Literature DB >> 2207329

Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit.

K C Day1, L C Hoffman, M O Palmier, K K Kretzmer, M D Huang, E Y Pyla, E Spokas, G J Broze, T G Warren, T C Wun.   

Abstract

Lipoprotein-associated coagulation inhibitor produces feed-back inhibition of tissue factor (tissue thromboplastin)-induced coagulation in the presence of factor Xa Recombinant lipoprotein-associated coagulation inhibitor (rLACI) was tested for its ability to modify thromboplastin-induced intravascular coagulation in a rabbit model that allows monitoring of iodine-125 fibrin accumulation/disappearance in the lung and sampling of blood for the measurement of coagulation parameters. Infusion of thromboplastin into the rabbit caused a rapid increase of radioactivity over the lungs, possibly due to the accumulation of 125I fibrin in the lungs, followed by a rapid decline of radioactivity, suggestive of removal of fibrin from the lungs. Thromboplastin also caused a rapid decrease of systemic fibrinogen that was accompanied by a lengthening of the activated partial thromboplastin time and prothrombin time. The effect of coinfusion of rLACI with thromboplastin or bolus injection of rLACI before thromboplastin infusion was studied. At a high dose of rLACI (800 micrograms/kg body weight), the thromboplastin-induced radioactivity increase in the lungs and the systemic fibrinogen decrease were completely suppressed. The activated partial thromboplastin time and prothrombin time of the plasma samples lengthened, possibly due to the presence of thromboplastin in circulation. The thromboplastin-induced radioactivity increase over the lungs was not completely suppressed by lower doses of rLACI (135 to 270 micrograms/kg body weight), but these doses of rLACI prevented systemic fibrinogen decrease. At a bolus dose of 23 micrograms/kg body weight, rLACI provided 50% protection of the fibrinogen consumption (fibrinogen decreased to 82% compared with 65% in rabbits treated with thromboplastin alone). These results show that rLACI is effective in the inhibition of thromboplastin-induced coagulation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207329

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Why does the blood not coagulate?

Authors:  O D Ratnoff
Journal:  West J Med       Date:  1993-02

2.  Determination of the disulfide bond pairings in human tissue factor pathway inhibitor purified from Escherichia coli.

Authors:  B N Violand; M R Schlittler; K L Duffin; C E Smith
Journal:  J Protein Chem       Date:  1995-07

3.  Tissue factor pathway inhibitor in childhood nephrotic syndrome.

Authors:  Mohamed M Al-Mugeiren; Abdel Galil M Abdel Gader; Saud A Al-Rasheed; Abdullah A Al-Salloum
Journal:  Pediatr Nephrol       Date:  2006-03-31       Impact factor: 3.714

4.  Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

Authors:  J H Erlich; J Apostolopoulos; T C Wun; K K Kretzmer; S R Holdsworth; P G Tipping
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

5.  The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

Authors:  I Warshawsky; G J Broze; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

Review 6.  Coagulation inhibitor substitution during sepsis.

Authors:  F Fourrier; M Jourdain; A Tournois; C Caron; J Goudemand; C Chopin
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

7.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Authors:  A A Creasey; A C Chang; L Feigen; T C Wün; F B Taylor; L B Hinshaw
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19.

Authors:  Abaher O Al-Tamimi; Ayesha M Yusuf; Manju N Jayakumar; Abdul W Ansari; Mona Elhassan; Fatema AbdulKarim; Meganathan Kannan; Rabih Halwani; Firdos Ahmad
Journal:  Int J Lab Hematol       Date:  2022-03-09       Impact factor: 3.450

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.